Ladon Therapeutics brings together breakthrough peptide chemistry and a state of the art diagnostic laboratory from gene expression profiling to in vivo disease models to characterize, test and evaluate ixPeptide® drug candidates.
Contact UsPharmacologically active peptides are a unique class of compounds with molecular weights from 300 to 5000 Da. They are considered as linear polymers of natural and/or artificial amino acids.
Considerable 3D structural instability at short chain-length. This limits their receptor binding potential.
Short half-life under physiological conditions due to intestinal proteolytic enzyme decomposition and rapid liver metabolization
Low membrane penetration potential. Contrary to small organic drug molecules, the limited passive movement of peptides through biological membranes prohibits their effective binding to intracellular targets.
The ixPeptide Platform is a breakthrough molecular solution for the custom design of selfassemling polypeptides. It increases the drug-likeness of the peptide molecules and creates first-in-class medicines to treat patients with major unmet clinical needs
Considerable 3D structural instability at short chain-lenght.
this limits their receptor binding potential.
Short half-life under physiological conditions due to intestinal proteolytic enzyme decomposition and rapid liver metabolization.
Low membrane penetration potential.
Contrary to small organic drug molecules, the limited passive movement of peptides through biological membranes prohibits their effective binding to intracellular targets.
The introduction of artificial amino acids enhances the stability of the 3D conformation. This results in an entropically more favored receptor binding profile.
Longer half-life under physiological condition due to the resistance to trypsin digestion
The introduction of positively charged residues in combination with a restricted secondary structure enables cell-membrane penetration.
HT based peptide synthesis and target identification & validation significantly reduce time to select lead candidates for drug development.
Gene expression analysis
Protein expression analysis
Histology
Immunohistochemistry
Immunofluorescent staining
2D cell culture models
3D organoid culture models
Signal transduction pathways
In vitro disease modelling
In vivo disease modelling
In vivo drug distribution analysis
Design and predict the structure and stability of peptides
Predict their binding to target proteins, and
Optimize their properties for the intended therapeutic applications.